Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,188,632

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,188,632 protect, and when does it expire?

Patent 10,188,632 protects VIBERZI and is included in one NDA.

This patent has twenty-nine patent family members in twenty countries.

Summary for Patent: 10,188,632
Title:Opioid receptor modulator dosage formulations
Abstract: Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Inventor(s): Costello; Tim (Wilmington, NC), Ceulemans; Jens Jozef (Beerse, BE), Jans; Eugeen Maria Jozef (Beerse, BE), Heyns; Philip Erna H. (Beerse, BE)
Assignee: Allergan Holdings Unlimited Company (Dublin, IE)
Application Number:15/588,304
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,188,632
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 10,188,632

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,188,632

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014241076 ⤷  Try it Free
Brazil 112015022753 ⤷  Try it Free
Canada 2906472 ⤷  Try it Free
China 105228629 ⤷  Try it Free
China 110917159 ⤷  Try it Free
Cyprus 1120892 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.